diagnost tool
price close busi june
market leader non-invas blood-
base prenat test enter larg liquid
biopsi cancer organ transplant test market
quietli check box transplant
target ye launch reiter top pick pt
reiter top pick follow compani announc
patient multi-cent prospect studi evalu prospera test kidney transplant
reject execut well base nipt busi acog catalyst
still aliv well make strong advanc oncolog transplant
pipelin despit return ytd believ under-valued
revenu peer group reiter buy rais pt
ntra kidney test prospera prospera test use quantifi
dd-cfdna transplant recipi without separ genotyp donor recipi vs
organ transplant reject test market leader allosur assay use
believ prospera differenti allosur high sensit
t-cell mediat antibodi mediat reject abil detect subclin
reject occur patient first year post-transpl
proactiv studi proactiv studi prospect enrol
kidney transplant patient time surgeri measur chang biopsi
usag clinic outcom base physician-direct use prospera test
rule-in rule-out activ reject studi follow patient year
follow subset high-risk patient year first patient expect
enrol prospera commerci launch later year
transplant leader rate driven
strong adopt allosur kidney transplant test part due dart studi
multicent prospect studi evalu patient year across
transplant center data compil visit continu
enrol patient k-oar studi patient trial aim toward
continu view transplant free call option complet analyt
clinic valid held pre-submiss meet obtain medicar draft local
coverag decis complet clia valid obtain z-code announc
year patient prospect registri studi target kidney test launch
end final medicar coverag think possibl launch
obtain final medicar coverag decis end ahead think
earlier year dont expect meaning revenu kidney
even model zero base conservat
anyth new acog spoke today manag comment
expect time new bulletin acog recal said around mid-year
immin ad medicaid payor averag risk nipt
discuss aet other addit blue plan
signatera oncolog launch yet well understood investor
launch uniqu signatera assay test cancer cancer
patient initi colon lung breast bladder cancer given sensit
specif data colon cancer recurr monitor good pre-sub
meet moldx expect signatera medicar coverag
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
rais pt despit move higher ytd trade
revenu estim materi coverag univers
averag revenu multipl pt formerli appli formerli
multipl revenu estim discount back two year
discount rate dilut share outstand includ proce
secondari offer earlier year hold cash later year
also may obtain payment partner bgi could take pro-forma cash
balanc million
model make chang model model continu assum zero
kidney transplant test though given compani rise traction view
estim conserv model revenu
respect model assum
oncolog revenu ruo signatera clinic test combin
respect
signatera oncolog launch yet well understood investor
addit compani plan launch blood-bas kidney transplant test
end recent launch uniqu signatera assay
test cancer cancer patient initi colon lung breast bladder
cancer top data resid plan charg somewher near
test cogs/test test self-pay basi build evid
reimburs if/when obtain reimburs signatera see
path reimburs cost good sold less
would nice accret compani gross margin
colon cancer test advanc given sensit specif data colon
cancer stage patient recurr monitor publish jama oncolog
pursu medicar coverag good pre-sub meet moldx
recent launch prospect trial expect medicar coverag
cancer data mount point see step-funct increas
stock multipl addit colon data breast cancer data
sensit specif publish clinic cancer research bladder
cancer sensit specif publish journal clinic oncolog
build landmark data lung cancer sensit specif
recent launch signatera huge billion cancer monitor market
address import unmet need determin cancer relaps american
cancer survivor year ahead imag therapeut monitor
like see data assert customized-to-the-pati
liquid biopsi typic track addit mutat lead panel
thu test may detect relaps anoth panel might miss indic
signatera liquid biopsi test detect circul tumor dna ctdna variant
allel frequenc vaf cell-fre dna provid deep depth
coverag expect addit studi demonstr signatera util come
acog expect steadi improv average-risk nipt reimburs
provid timet acog decis spoke
manag topic today manag provid specif time
updat indic call new guidanc way
support averag risk nipt still wait acog publish
new bulletin remain activ engag aet think
coverag polici decis inevit remind get paid
time average-risk nipt volum think reason could get
paid roughli time least end view expect
payor outsid aet come well time
step-funct increas pharma revenu build confid target
contract valu pharma increas vs
cumul contract valu driven pharma interest
signatera ruo test minim residu diseas mrd molecular monitor
natera indic contract valu convert revenu cours
month thu expect modest contribut oncolog
revenu pick beyond studi trial
pharma compani includ pharma lead io compani
buy unchang target price june
diagnost tool
studi trial cancer indic lung
breast colon prostat pan-canc applic one notabl exampl bm
use help determin patient receiv chemo alon chemo
opdivo expect mani deal come meaning econom
million bgi deal earlier year announc deal bgi
genom call indic expect net cash up-front
bgi deal manag treat cash payment
plan recogn futur work revenu agreement
bgi pay million up-front licens fee prepaid royalti
also receiv on-going royalti payment manag indic
call expect sum ten million dollar time think
unreason given million peopl china live cancer
number american live cancer accord
prepay bgi genom sequenc servic reagent relat
partnership ntra signatera mrd minim residu diseas molecular
monitor test offer china first specialti hospit network without
need cfda approv broadli follow like cfda regulatori approv
signatera mrd bgi dnbseq instrument platform indic call
cfda approv burdensom process suggest bgi may
commerci signatera test china believ investor treat
entir opportun free call option opportun bake
either multipl stock forward year sell-sid consensu revenu
estim
bgi enabl offer huge import china market bgi provid
highli respect partner larg china market further global
expans goal use import supplier chang
exist suppli agreement held posit sequenc
agnost decentr test enabl peopl world run test sampl
local site sequenc vs send sampl ntra lab ca
done partnership bgi think remind investor
deal announc strictli relat pre-nat test
thu think done announc addit strateg deal believ
would logic want access compel oncolog test menu
even see partnership outsid bgi recal work
thermo fisher subsidiari alreadi one lambda transplant market thu
rule possibl sign deal thermo use ion torrent
buy unchang target price june
diagnost tool
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
buy unchang target price june
diagnost tool
buy unchang target price june
diagnost tool
buy unchang target price june
diagnost tool
